基于IMpower 133批准Atezolizumab联合化疗(卡铂+依托泊苷)一线治疗ED-SCLC,这个FDA3月份已经批准,先前也有报道,不再赘述。 基于IMpower 130批准Atezolizumab联合化疗(卡铂+白蛋白紫杉醇)一线治疗无EGFR和ALK突变的non-sq NSCLC,FDA在2019年1月16日接受sBLA,需要在9月2日做出决定。 IMpower130旨在评估Atezolizumab+化疗(卡...
但由于预设的是全人群的分析,所以PR在non sq 亚组中不能claim stat significant,可以看对于PFS的写法。 datopotamab deruxtecan demonstrated a statistically significant improvement in PFS in the overall trial population and a clinically meaningful PFS benefit in patients with nonsquamous NSCLC. 所以在non ...
EGFR mutation testing trends for patients with metastatic, non-squamous non-small cell lung cancer (non-SQ NSCLC) in Queensland, Australia from 2014-2021.doi:10.1200/JCO.2024.42.16_suppl.e1350563e13505#Background:Lung cancer is the leading cause of cancer-related mortality worldwide. Epidermal ...
30MO ORIENT-3: A randomized, open-label, phase III study of sintilimab versus docetaxel in previously treated advanced/metastatic squamous non-small cell lung cancer (sqNSCLC) 喜欢 0 阅读量: 172 作者:Y Shi,L Wu,X Yu,P Xing,Y Zhao ...
Paclitaxel-induced inhibition of NSCLC invasion and migration via RBFOX3-mediated circIGF1R biogenesis Zhanyu Xu Liping Zheng Shikang Li Scientific Reports(2024) Vangl-dependent Wnt/planar cell polarity signaling mediates collective breast carcinoma motility and distant metastasis ...
This phase III trial (NCT02810457) compared the efficacy and safety of FKB238 with that of bevacizumab in patients with advanced/recurrent non-squamous non-small-cell lung cancer (non-sq-NSCLC). Methods This global, multicenter, double-blind, parallel, randomized, comparative clinical trial enrolle...
基于IMpower 130批准Atezolizumab联合化疗(卡铂+白蛋白紫杉醇)一线治疗无EGFR和ALK突变的non-sq NSCLC,FDA在2019年1月16日接受sBLA,需要在9月2日做出决定。 IMpower130旨在评估Atezolizumab+化疗(卡铂+白蛋白紫杉醇)对比化疗一线治疗IV期non-sq NSCLC,者按2:1随机分配至联合组(Atezolizumab+化疗治疗4-6个疗程后Atezoli...
O3-097 * PHASE II STUDY OF BEVACIZUMAB PLUS CBDCA/PAC AS FIRST LINE CHEMOTHERAPY FOR NON-SQ NSCLC WITH MALIGNANT PLEURAL EFFUSIONAnnals of Oncology
H48Retrospective evaluation of chemotherapy options in non-squamous non-small cell lung cancer (non-Sq NSCLC) patients (pts) unfit for standard platinum-based chemotherapy in clinical practicedoi:10.1093/annonc/mdv343.48A. CortelliniG. Bruera
Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is an effective treatment for advanced non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations. However, there have been little evidence-based studies of gefitinib in combination with platinum-...